AVI BioPharma to Present at the 29th Annual JPMorgan Healthcare Conference
January 06 2011 - 8:00AM
Marketwired
AVI BioPharma (NASDAQ: AVII), a developer of RNA-based drugs,
announced today that the company is scheduled to present at the
29th Annual JPMorgan Healthcare Conference in San Francisco on
Thursday, January 13, at noon Pacific Time. Chris Garabedian, AVI's
president and CEO, will provide a company overview.
The conference presentation will be webcast live under the
events section of AVI's website at www.avibio.com, and will be
archived there following the presentation. Please connect to AVI's
website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be
necessary.
About AVI BioPharma AVI BioPharma is
focused on the discovery and development of novel RNA-based
therapeutics for rare and infectious diseases, as well as other
select disease targets. Applying pioneering technologies developed
and optimized by AVI, the Company is able to target a broad range
of diseases and disorders through distinct RNA-based mechanisms of
action. Unlike other RNA-based approaches, AVI's technologies can
be used to directly target both messenger RNA (mRNA) and precursor
messenger RNA (pre-mRNA) to either down-regulate (inhibit) or
up-regulate (promote) the expression of targeted genes or proteins.
By leveraging its highly differentiated technology platform, AVI
has built a pipeline of potentially transformative therapeutic
agents, including a clinical stage Duchenne muscular dystrophy
candidate and anti-infective candidates for influenza and
hemorrhagic fever viruses. For more information, visit
www.avibio.com.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024